8.2 million euros in seed funding Aeon wants to redefine prevention

Swiss HealthTech startup Aeon secures €8.2 million in seed capital to scale its AI-powered platform for personalized preventive medicine in Europe.

Berlin, June 4, 2025 - Aeon, a Swiss HealthTech founded in 2024, has closed an €8.2 million seed funding round. The round was led by London-based VC Concentric, with participation from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR and prominent Swiss angel investor Daniel Gutenberg. Aeon intends to use the capital to roll out its AI-based platform for the early detection of diseases across Europe. This also includes planned new locations in Germany, Switzerland and the UK.

Whole-body MRI, genetics and blood values on one platform

Aeon combines medical diagnostic procedures such as whole-body MRI, genetic analysis and advanced blood tests with AI-supported evaluation.

Our goal is a new era of preventive medicine - proactive, precise and medically sound.

Tim Seithe, CEO Aeon

The check-up takes around 60 minutes, covers over 500 disease indicators and, according to the company, provides clinically validated, personalized risk profiles. The results are discussed by doctors and made available in a user-friendly app. With the aim of avoiding overdiagnosis, the rate of false-positive findings is 0% so far, according to Aeon.

Health insurance reimbursement as a unique selling point

Aeon claims to be the first platform for full-body check-ups whose services are partially reimbursed by health insurance companies, such as the Swiss KPT insurance company. Depending on the policy, up to 75% of costs can be reimbursed.

AI applications in prevention

Aeon's AI technology provides support in three key areas:

• Automated image analysis: AI detects and quantifies anomalies on MRI images.
• Cross-validation: Linking of MRI, blood and gene data to minimize false-positive results.
• Risk profiling: Creation of personalized health prognoses with specific prevention recommendations.

Rapid growth and scaling plans

Aeon plans to use the fresh capital to open over ten new locations in the coming months. The initial focus will be on the DACH region, Switzerland, the UK and the development of insurance and employer partnerships. "Aeon offers one of the most medically robust products in the prevention sector today," says Alex Stroud, Principal at lead investor Concentric.

In addition to CEO Tim Seithe, Samuel Frey (formerly Platomics) is part of the founding team as CPO. They are supported by Dr. Andreas Lemke, one of Europe's leading MRI physicists and founder of the MedTech company Mediaire.